United Therapeutics (NASDAQ: UTHR) pushes inhaled therapy strategy as Phase 3 Tyvaso data shows lung function preservation in IPF
Read More 2 minute read Pharma Industry News Olatec Therapeutics set to launch dapansutrile Phase 2 trial in Parkinson’s disease Olatec Therapeutics, Inc. (Olatec), a leader in the field of selective NLRP3 inhibitors, has embarked on a journey… byPallavi MadhirajuFebruary 20, 2024